DGAP-News: 4SC AG / Key word(s): Half Year Results
08.08.2019 / 07:30
The issuer is solely responsible for the content of this announcement.
4SC AG provides Q2 and H1 2019 update
Conference call scheduled for today, 8 August 2019, 2 pm CEDT (8 am EDT)
Planegg-Martinsried, Germany, 8 August 2019 – 4SC AG (4SC, FSE Prime Standard: VSC) today published its Half-Year Report and provided a business update for the six months ended 30 June 2019 as well as the Company’s current outlook. The full report is available for download on 4SC’s webpage.
Key highlights of Q2 2019 and beyond
Cash balance development in H1 2019 and financial forecast
4SC held cash balance/funds amounting to EUR 17.8 million at the end of H1 2019. Taking into account the proceeds from the June 2019 cash capital increase in the net amount of circa EUR 10.5 million, current financial planning and the intended operational activities, the Management Board of 4SC maintains its existing financial forecast for the full year 2019 of an average monthly use of cash from operations of between EUR 1.4 million and EUR 1.6 million. The planned extension of the development program is subject to further financing. The Management Board estimates that current funds should be sufficient to finance 4SC for at least the next twelve months.
4SC will host a conference call today at 2 pm CEDT (8 am EDT) to discuss the key developments in the reporting period and beyond.
Interested investors, analysts, and journalists can access the call via the telephone numbers stated below. Please join the event conference 5-10 minutes prior to the start time. You will be asked to provide the confirmation code.
A presentation document supporting the conference call is available at 4SC’s website. After the event, a replay can be accessed from there as well.
– Press release ends –
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. 4SC’s pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development: resminostat and domatinostat.
4SC aims to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself.
4SC is headquartered in Planegg-Martinsried near Munich, Germany. The Company had 47 employees as of 30 June 2019 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A14KL72).
Information set forth in this press release contains forward-looking statements, which involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond 4SC’s control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
08.08.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Phone:||+49 89 700763-0|
|Fax:||+49 89 700763-29|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||852437|
|End of News||DGAP News Service|